On June 18, 2024, NANOBIOTIX hosts a virtual KOL event discussing NBTXR3 combined with immunotherapy in head and neck cancer.

NANOBIOTIX, a late-clinical stage biotech company, announces a virtual KOL event on June 18, 2024. The event will discuss the potential of NBTXR3 combined with immunotherapy in head and neck cancer and beyond. Key Opinion Leaders (KOLs) including Study 1100 Coordinating Investigators Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman will participate, with Dr Sebastien Paris, PhD, moderating the event.

June 12, 2024
3 Articles